allergic diseases

Actionable Insights Powered by AI

Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4

Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases